Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CDCareDx, Inc logo

CareDx, Inc (CDNA)

NASDAQ Global Market · Currency in USD
$69.21 ▲ +0.05 (+0.07%)
At close: Oct 23, 4:00 PM ET. Market closed.
$69.42 ▲ +0.21 (+0.30%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$69.16
Open
$68.54
Day's Range
$67.74 – $70.47
52 Week Range
$14.23 – $72.71
Volume
745,878
Avg. Volume
1,247,589
Market Cap
$3.58B
Beta (5Y Monthly)
2.38
PE Ratio (TTM)
32.16
EPS (TTM)
$2.16
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$62.25

Profile: CareDx, Inc

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
763
CEO
John Walter Hanna Jr.
Website
caredx.com

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $0.25 · Revenue est. $121.95M
DateEst.Actual
Jul 30, 2026$0.23$0.37Beat
Apr 28, 2026$0.11$0.34Beat
Feb 24, 2026$0.02$0.12Beat
Nov 4, 2025-$0.08$0.03Beat
Aug 6, 2025-$0.10-$0.16Miss
Apr 30, 2025-$0.21-$0.19Beat

Analyst view

Consensus price target
$62.25 ▼ -10.1%
Range $46.00 – $74.00
Rating: Buy
Buy 79% · Hold 21% · Sell 0%

Get free alerts on CDNA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.